


A Manganese Alternative to Gadolinium for MRI Contrast

Eric M. Gale,* Iliyana P. Atanasova, Francesco Blasi, Ilknur Ay, and Peter Caravan*

The Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Suite 2301, Charlestown, Massachusetts 02129, United States

Supporting Information

ABSTRACT: Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) are routinely used to diagnose soft tissue and vascular abnormalities. However, safety concerns limit the use of iodinated and gadolinium (Gd)-based CT and MRI contrast media in renally compromised patients. With an estimated 14% of the US population suffering from chronic kidney disease (CKD), contrast media compatible with renal impairment is sorely needed. We present the new manganese(II) complex $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ as a Gd alternative. $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ is among the most stable Mn(II) complexes at pH 7.4 ($\log K_{\text{ML}} = 11.40$). In the presence of 25 mol equiv of Zn at pH 6.0, 37 °C, $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ is 20-fold more resistant to dissociation than $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$. Relaxivity of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ in blood plasma is comparable to commercial Gd contrast agents. Biodistribution analysis confirms that $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ clears via a mixed renal/hepatobiliary pathway with >99% elimination by 24 h. $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ was modified to form a bifunctional chelator and 4 chelates were conjugated to a fibrin-specific peptide to give Mn-FBP. Mn-FBP binds the soluble fibrin fragment DD(E) with $K_{\text{d}} = 110$ nM. Per Mn relaxivity of Mn-FBP is 4-fold greater than $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ and increases 60% in the presence of fibrin, consistent with binding. Mn-FBP provided equivalent thrombus enhancement to the state of the art Gd analogue, EP-2104R, in a rat model of arterial thrombosis. Mn metabolite analysis reveals no evidence of dechelation and the probe was >99% eliminated after 24 h. $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ is a lead development candidate for an imaging probe that is compatible with renally compromised patients.



INTRODUCTION


Chronic kidney disease (CKD) affects 14% of the US adult population, and this prevalence is increasing with the epidemic of diabetes.¹ CKD is characterized by progressive deterioration of renal function (staged 1–5 by glomerular filtration rate (GFR)) that culminates in kidney failure. Poor kidney function is often associated with other comorbidities. For instance, 86% of patients with stage 4 CKD suffer at least one comorbidity.² Along with diabetes, the most commonly experienced comorbidities are cardiovascular disease and hypertension, as many facets of cardiovascular physiology are intimately linked to kidney function.^{2–4} This is a patient population that will benefit from contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) to detect disease, to monitor disease progression, and to guide therapeutic decisions. Because CKD is so prevalent, these patients may also require imaging for other pathologies unassociated with CKD, e.g., malignancies.

Unfortunately, routinely ordered contrast enhanced imaging protocols are incompatible with renal compromise. For the estimated 7.7% of US adults experiencing moderate to severe CKD (stage 3 and higher),⁵ the iodinated contrast media used to delineate vascular and soft tissue structures in CT scans carries the risk of a severe and sometimes irreversible loss of renal function termed contrast induced nephropathy (CIN).^{6,7} Gadolinium (Gd)-based imaging probes used in contrast-

enhanced MRI are linked to the onset of nephrogenic systemic fibrosis (NSF), a rare but severe and potentially fatal fibrosis of the skin and internal organs that can arise in renally impaired patients.^{8,9} The risk of both CIN and NSF increases with decreasing GFR. Iodinated radiocontrast and 3 Gd-based MR probes comprised of acyclic chelates are contraindicated for patients staged CKD ≥ 3 .^{6,7,10} It is worth noting that macrocycle based Gd-imaging probes exhibit superior stability and inertness relative to the acyclic probes and there are few unconfounded accounts linking NSF to macrocycle based Gd probes. Despite this fact, all Gd-based probes come with an FDA black box warning and American College of Radiology guidelines advise against the use of any Gd in patients suffering acute kidney injury or with $\text{GFR} < 40$ mL/min/1.73m².¹¹ As a result, patients are often not imaged and clinicians must make management decisions with limited diagnostic information.¹² More recently, a number of reports have identified dose dependent Gd accumulation in the brains of patients with normal renal function that have received contrast enhanced MRI,^{13–18} raising further concerns by the FDA regarding this class of compounds. Gadolinium retention in a subset of patients further underscores the need for Gd-free alternatives to enhance MR contrast.

Received: October 14, 2015

Published: November 20, 2015

Scheme 1. Synthesis of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^{-4}$ 

^a(a) Substoichiometric benzyl bromide, MeCN, RT; (b) 3 equiv of ^tbutyl-bromoacetate, 1 equiv of KI, DIPEA, DMF, RT; (c) 1 atm H₂ (g), 10% by wt. Pd/C, MeOH; (d) picolyl chloride, KI, DIPEA, DMF, RT; (e) 1:1 CH₂Cl₂:TFA, RT; (f) MnCl₂, pH 6.5.

The development of safe alternative imaging probes that are compatible with renal insufficiency stands to profoundly impact patient outcomes within a large and challenging population. The ideal probe would be amenable to as broad a range of imaging applications as the routinely used iodinated CT contrast and Gd-based MR probes. The probe should freely distribute in the blood and in the extravascular, extracellular space and then clear rapidly. At least partial nonrenal excretion must occur to circumvent the clearance barrier imposed by renal compromise. The probe should also enhance image contrast with sensitivity comparable to or better than currently used imaging probes.

Several classes of imaging probes have been considered as alternatives but all have drawbacks. Nanoparticles, e.g., iron oxides, generate superb MR image contrast but their large size limits their use to angiography, liver imaging, and niche applications targeting macrophages.¹⁹ Furthermore, the adverse effect profile of nanoparticles is troubling. Ferumoxytol is associated with severe anaphylaxis and at least 18 patients deaths and now also carries an FDA black box warning.²⁰ MR imaging probes that provide contrast via chemical exchange saturation transfer or direct detection of NMR active nuclei require at least an order of magnitude higher doses compared to Gd-based probes.²¹ Nuclear medicine techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) are highly sensitive but do not provide spatial resolution sufficient to delineate many vascular and tissue abnormalities.²²

Manganese (Mn)-based complexes have also been considered as Gd-alternatives. The Mn²⁺ ion exhibits all of the physical properties that make Gd³⁺ a highly efficient imaging probe in T₁-weighted MR protocols: both ions are characterized by high spin quantum number ($S = 7/2$ for Gd³⁺, $S = 5/2$ for Mn²⁺), long longitudinal electronic relaxation times, and fast water exchange kinetics.^{22,23} Mn is biogenic, and intravenously administered Mn²⁺ is cleared via biliary excretion, a particularly attractive feature in the context of renal compromise. Indeed, the complex [Mn(DPDP)]³⁻ (Figure S6) was approved for use as a liver imaging agent.^{24,25} It was shown that [Mn(DPDP)]³⁻ undergoes partial dechelation in plasma and the Mn²⁺ ion is then rapidly taken up by hepatocytes, pancreatic tissue and cardiomyocytes.^{26,27} [Mn(DPDP)]³⁻ highlights both the promise and challenge of using Mn²⁺. On the one hand [Mn(DPDP)]³⁻ generated exquisite image contrast demonstrating the efficacy of a Mn-based approach, on the other hand [Mn(DPDP)]³⁻ highlights the extreme lability of the Mn²⁺ ion and the challenge of designing a stable Mn-chelate.

We set out to rationally design chelators that afford stable Mn²⁺ complexes suitable for the same MR imaging applications as Gd-based probes: small, hydrophilic complexes useful for angiography,^{28,29} lesion identification,^{30,31} and characterization of tissue perfusion,³² as well as bifunctional Mn²⁺ chelators that

can be used in molecular MR applications. Here we introduce a new chelator PyC3A that forms a stable, inert complex with Mn²⁺ and provides equivalent relaxivity to Gd-based chelates used clinically. A bifunctional version of PyC3A enables the development of targeted probes and here we demonstrate a fibrin-targeted Mn-based probe for molecular imaging of thrombosis. We first characterized the thermodynamic stability, kinetic inertness with respect to transmetalation, relaxivity, hydration state, and water exchange kinetics of the Mn-complexes. For the fibrin-targeted probe we characterized its fibrin binding properties and relaxivity, and then compared it to a known Gd-based fibrin probe with MR imaging in a rat model of thrombosis. Detailed pharmacokinetic and biodistribution studies were performed to establish the in vivo stability of the Mn-chelate, and to show that it is completely excreted.

RESULTS

Design and Synthesis of Mn-Based Imaging Probe.

We outlined several design criteria at the outset of this work to address safety and efficacy. First, we aimed to maximize the thermodynamic stability of the Mn-chelate. Equally important, the chelate must be inert to Mn²⁺ dissociation. High T₁-relaxivity ($r_1 = \Delta(1/T_1)/[\text{Mn}]$) is another requisite. In order to achieve high relaxivity there must be a water coligand that undergoes relaxation and rapid exchange with bulk solvent.^{23,35} The imaging probe should be hydrophilic and anionic to promote both high solubility for formulation as well as a likely extracellular distribution. We also sought a modest degree of lipophilicity to promote at least partial biliary clearance. Finally, the chelator should also be readily amenable to synthetic modulation for further optimization or bioconjugation. The Mn²⁺ chelator *N*-picolyl-*N,N',N'*-*trans*-1,2-cyclohexylenediaminetriacetate (PyC3A, Scheme 1) meets these criteria. A survey of the coordination chemistry literature reveals that at pH 7.4 the most stable Mn²⁺ complexes are formed from polyaminocarboxylate ligands (Figure S6, Table S1). Hexadenate, acyclic ligands such as EDTA tend toward ternary, heptacoordinate Mn²⁺ complexes with a labile water coligand, which provide suitable relaxivity.^{34,36–38} On the other hand the most stable Mn²⁺ macrocyclic complexes have no water coligand.³⁹ We know from prior experience with Mn²⁺ complexes of the ligand HBET and various derivatives (Figure S6) that replacement of a single acetate-O donor with a different donor group results in complexes of comparable stability without precluding coordination of a water coligand.³⁴

The *trans*-1,2-cyclohexylene linkage and pyridyl-*N* donor were incorporated within the chelate backbone to promote kinetic inertness with respect to Mn²⁺ dissociation. The propensity of the *trans*-1,2-diaminocyclohexane backbone to promote kinetic inertness is well documented, and has been shown to decrease the Mn²⁺ dissociation rate in the presence of competing metal ions by 4 orders of magnitude compared to an ethylene backbone.³³ The pyridyl-*N* donor was incorporated

Table 1. Protonation^a and Formation^b Constants of Ligands and Their Corresponding Mn(II) Complexes

	log K_{LH}	log K_{LH_2}	log K_{LH_3}	log K_{LH_4}	log K_{ML}	log K_{MLH}	log $K_{pH\ 7.4}^c$	pMn (pH 7.4) ^d
PyC3A	10.16 ± 0.02	6.39 ± 0.04	3.13 ± 0.03	–	14.14 ± 0.01	2.43 ± 0.03	11.34, 11.40 ± 0.13 ^e	8.17, 8.20 ^e
EDTA	9.17, ³³ 9.35 ³⁴	5.99 ³³ 5.98 ³⁴	2.73, ³³ 2.48 ³⁴	2.01, ³³ 2.23 ³⁴	12.46, ³³ 12.61 ³⁴	2.95, ³³ 2.90 ³⁴	10.49, ³³ 10.67 ³⁴	7.82, ³³ 7.83
CDTA	9.36, ³³ 9.43 ³⁴	5.95, ³³ 6.01 ³⁴	3.62, ³³ 3.68 ³⁴	2.57, ³³ 2.51 ³⁴	14.32, ³³ 14.69 ³⁴	2.90, ³³ 2.42 ³⁴	12.34, ³³ 12.64 ³⁴	8.67, ³³ 8.82

^aValues were obtained by pH-potentiometry (25 °C, $I = 0.15$ M NaCl). K_{LH_n} defined as $[H_nL]/([H][H_{n-1}L])$. ^b K_{ML} defined as $[ML]/([M][L])$; K_{HML} defined as $[HML]/([ML][H])$ (charges omitted for clarity). ^cEffective formation constant at pH 7.4. ^dpMn defined as $-\log[\text{free Mn}]$ when $[M] = [L] = 10\ \mu\text{M}$. ^eValue obtained from K_{comp} determined using CDTA challenge.

with the aims of further rigidifying the chelate, adding additional lipophilic character to the chelate, and to add an achiral point of synthetic elaboration for molecular imaging applications. Prior NMR studies have demonstrated that metal complexes of acyclic pyridyl-*N* containing chelates exhibit a lesser degree of fluxionality in solution than those formed by analogous chelates featuring acetate-*O* donors instead.⁴⁰ We rationalized that this effect will boost kinetic inertness. We also rationalized that the *trans*-1,2-cyclohexanediamine linkage and pyridyl-*N* donor combine could provide sufficient lipophilic character to promote hepatic uptake, and thus partial nonrenal clearance of the resultant anionic Mn complex. The pyridyl-*N* group is highly modular and provides easy access to bifunctional derivatives for bioconjugation and molecular imaging.

PyC3A is prepared in 5 steps (Scheme 1). Monobenylation of *trans*-1,2-diaminocyclohexane followed by exhaustive alkylation with ^tbutyl bromoacetate, then benzyl deprotection via hydrogenation over Pd/C yields *N,N,N'*-*trans*-1,2-cyclohexylenediaminetri-^tbutylacetate (3), a synthon common to both PyC3A and its bifunctional derivative (see below). Reaction of 3 with picolyl chloride followed by removal of the ^tBu protecting groups in neat TFA yields PyC3A, isolated as PyC3A·TFA. $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ was prepared by mixing the ligand with 1 mol equiv of MnCl₂ in water and adjusting the pH to 6.5.

Physicochemical Evaluation of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$.

$[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ is among the most thermodynamically stable Mn²⁺ complexes reported (Table S1). Ligand protonation constants and Mn²⁺ thermodynamic stability constants in 0.15 M NaCl, 25 °C, were determined by pH-potentiometry (Table 1). The thermodynamic stability constant at pH 7.4 was also measured through direct competition with CDTA monitored using LC-MS (Figure S9). Potentiometric titration (Figure 1A) yields a stability constant log $K = 14.14$, and a conditional stability constant log $K_{pH\ 7.4} = 11.34$ which is in excellent agreement with log $K_{pH\ 7.4} = 11.40$ calculated from the CDTA challenge. Figure S10 depicts Mn²⁺ composition as a function of pH in a solution containing 1 mM each Mn²⁺ and PyC3A, 0.15 M NaCl, 25 °C and demonstrates that complexation is complete by pH 4.5.

$[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ is also very inert to Mn²⁺ transmetalation. We stressed the complex under two sets of extreme conditions and compared the rates of metal ion displacement to other stable Mn²⁺ and Gd³⁺ complexes. Kinetic inertness was evaluated by challenging $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ with 25 mol. equiv Zn²⁺ at pH 6.0, 37 °C, and using relaxivity as a readout. The transmetalation kinetics of $[\text{Mn}(\text{CDTA})(\text{H}_2\text{O})]^{2-}$ and $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$ were measured as comparative benchmarks. Of previously reported Mn²⁺ complexes, $[\text{Mn}(\text{CDTA})(\text{H}_2\text{O})]^{2-}$ is the most kinetically inert system that allows direct Mn²⁺-water interaction and thus sufficient relaxivity.³³ $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$ is the active ingredient in Magnevist, the




Figure 1. (A) pH titration of PyC3A·TFA in the absence (L) and presence (ML) of 1 equiv of MnCl₂ at 25 °C, $I = 0.15$ M NaCl. (B) Transmetalation of 1 mM $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$ (filled diamonds), $[\text{Mn}(\text{CDTA})(\text{H}_2\text{O})]^{2-}$ (open circles) or $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ (filled circles) by 25 mM Zn²⁺ monitored by relaxivity change as a function of time in 50 mM pH 6.0 MES buffer, 37 °C, 1.4 T. (C) H₂¹⁷O transverse relaxivity in the presence of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ as a function of temperature. Solid lines are fits to the data. (D) r_1 of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ measured in pH 7.4 Tris buffer, bovine blood plasma, and 4.5 wt %/v bovine serum albumin (BSA) at 1.4 T, 37 °C.

most widely used clinical MR contrast agent. Mn²⁺ displacement was recorded by measuring solvent T₂ as a function of time, as r_2 of free Mn²⁺ is ~30-fold that of the chelated, monohydrated ion (Figure 1B),⁴¹ Gd³⁺ displacement was measured via monitoring T₁ change. These experimental conditions allowed for homogeneous reaction mixtures and rapid data acquisition.

$[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ was 2-fold more inert to Zn²⁺ challenge than $[\text{Mn}(\text{CDTA})(\text{H}_2\text{O})]^{2-}$ and 20-fold more inert than $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$. Pseudo-first-order rate constants were $6.76 \pm 0.03 \times 10^{-4}$, $1.10 \pm 0.01 \times 10^{-3}$ and $1.41 \pm 0.31 \times 10^{-2}\ \text{s}^{-1}$ for $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$, $[\text{Mn}(\text{CDTA})(\text{H}_2\text{O})]^{2-}$ and $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$, respectively. Prior accounts characterizing Mn²⁺ transmetalation using various chelates including CDTA indicate spontaneous MLH dissociation as the predominant pathway,^{33,39,42–45} and $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ transmetalation likely proceeds through an analogous mechanism. We expect the relative inertness observed at pH 6 to remain constant across the range of pH potentially encountered in vivo. We also evaluated $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ under a standard set of conditions used to comparatively evaluate the inertness of Gd complexes, i.e., challenge with Zn²⁺ and phosphate ion at pH 7 (Figures S11–12). Under these conditions, $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ showed similar inertness to the approved acyclic Gd-based contrast agent $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$.

The temperature dependence of bulk water ^{17}O T_2 (Figure 1C) demonstrates that an inner-sphere water coligand is present in $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$, and that this water undergoes very fast exchange with solvent.^{46,47} The water exchange rate at 37 °C for $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ is $k_{\text{ex}} = 1.0 \times 10^8 \text{ s}^{-1}$; associated kinetic parameters are listed in Table 2.

Table 2. Hydration State (q), Water Exchange Parameters and Mn– ^{17}O Hyperfine Coupling Constant (A_0/\hbar) of Corresponding Mn(II) Complexes

	q	$k_{\text{ex}}^{310} (\times 10^8 \text{ s}^{-1})$	ΔH^\ddagger (kJ/mol)	$A_0/\hbar (\times 10^7 \text{ rad/s})$
$[\text{Mn}(\text{PyC3A})]^-$	1	1.0 ± 0.02	37.2	2.87 ± 0.080
Mn-FBP	1	1.1 ± 0.04	39.7	2.82 ± 0.040

The relaxivity of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ in blood plasma is equivalent to clinical Gd-based contrast agents such as $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$ (Figures 1D and S8, Table S3). Relaxivity measurements were performed at 1.4 T, 37 °C. Relaxivity was $2.1 \text{ mM}^{-1} \text{ s}^{-1}$ in pH 7.4 buffer and increased to $3.8 \text{ mM}^{-1} \text{ s}^{-1}$ in bovine blood plasma, similar to Gd-DTPA and Gd-DOTA (4.1 and $3.6 \text{ mM}^{-1} \text{ s}^{-1}$ in plasma).⁴⁸ The near doubling in r_1 observed in plasma is attributed to low-affinity interactions with serum proteins, which increases relaxivity at 1.4 T.^{23,35,37,41} Indeed, similar r_1 ($3.4 \text{ mM}^{-1} \text{ s}^{-1}$) is measured in 4.5% w/v BSA solution. Weak protein binding was confirmed by measurement of the fraction of protein bound $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ by ultrafiltration through a 5 kDa cutoff membrane and revealed that for a 150–300 μM $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ solution, 1–5% is protein bound in both plasma and 4.5% w/v BSA solutions.

$[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ Is an Effective MRI Contrast Agent with Rapid Renal and Hepatic Clearance in Mice. Key criteria in the development of a Gd-alternative are (1) extracellular distribution, (2) rapid clearance, and (3) mixed

renal and hepatic elimination. We used dynamic MRI to assess these criteria in mice. Figure 2A–C show a series of coronal MR images prior to, 3, and 25 min following intravenous administration of 60 $\mu\text{mol/kg}$ $\text{Na}[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$. After initial blood pool enhancement, the compound is rapidly cleared from the blood. Elimination occurs through the kidneys and into the bladder, but also through the liver. We drew regions of interest (ROIs) on the left ventricle of the heart (blood), the liver, and kidney, and measured the change in normalized signal-to-noise ratio (nSNR) as a function of time. Figure 2D–F depict nSNR for the blood, kidney, and liver. The nSNR vs time curves were fit to a monoexponential for each animal to obtain a half-life for the probe in that tissue, and then the mean half-life was calculated using the data from the 4 animals. The kinetics of blood clearance, $t_{1/2} = 7.8 \pm 3.0 \text{ min}$, is similar to small Gd-based chelates in mice. These imaging studies demonstrate that $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ provides good image contrast, has the expected extracellular distribution, and is rapidly cleared via a mixed renal/hepatic pathway. Mn tissue content was determined by ICP-MS 24 h following probe injection ($N = 4$) and compared against endogenous Mn levels recorded in naïve mice ($N = 4$) (Figure 3). At 24 h, < 0.05% injected dose per gram of tissue (% ID/g) remains in the liver and kidneys while Mn levels in all other tissues are not elevated above endogenous basal levels.

Design and Synthesis of Fibrin-Targeting Probe Mn-FBP. Encouraged by the favorable relaxivity and stability profile of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$, we sought to directly apply the complex to a targeted molecular imaging application. We chose fibrin, a principal component of thrombus (blood clot), as our molecular target. Fibrin is an insoluble polymeric protein network that forms following vascular insult via protease action of thrombin on the serum constituent protein fibrinogen. Enzymatic cross-linking fortifies the fibrin network. Fibrin is present at >10 μM concentration in thrombi and thus




Figure 2. Coronal T_1 -weighted MR images of a balb/C mouse acquired prior to (A), 3 min (B), and 25 min (C) following i.v. administration of 60 $\mu\text{mol/kg}$ $\text{Na}[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$. Normalized signal-to-noise ratio (nSNR) as a function of time in the blood (D), kidney (E), and liver (F) following $\text{Na}[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ injection; $N = 4$, error bars represent standard error of the mean; solid lines are monoexponential fits to the mean data.





Figure 3. Endogenous Mn concentration (nmol/g) in mouse tissues (gray bars, $N = 4$, determined from naive mice) and Mn tissue levels 24 h following intravenous injection of $60 \mu\text{mol/kg}$ $\text{Na}[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]$ (black bars, $N = 4$). Statistically elevated Mn levels (*, $P < 0.05$) were observed only in the kidney and liver and together represent $<0.05\%$ of the injected dose per gram tissue.

represents a sufficiently abundant target for molecular MR imaging.²² Molecular imaging of fibrin could be used to detect the culprit lesion or source embolus in various thromboembolic diseases such as heart attack, stroke, deep vein thrombosis, or pulmonary embolism.

We used a short cyclic peptide shown to have high selectivity for fibrin over serum proteins.^{49–51} This peptide was previously modified to enhance fibrin affinity and conjugated to imaging reporters (PET, MR, optical) for fibrin imaging in animal models of thrombosis and cancer.^{52–56} A highly optimized Gd-based derivative, EP-2104R, was used to detect thrombi in humans.^{57,58} We sought to develop a conjugate similar to EP-2104R using $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ in order to compare how the Mn-chelate compared to Gd in a well established molecular probe.

The pyridyl moiety provides an easy and achiral means to incorporate additional functionality at a position remote from the Mn ion. The 5-position was substituted to prepare the bifunctional chelate $t\text{Bu-PyC3A-NHS}$ (Scheme 2). Coupling of **5** (prepared in 2 steps) to **3** was followed by LiOH hydrolysis

Scheme 2. Synthesis of Mn-FBP^{4a}



^a(a) *N*-Bromosuccinimide, cat. benzoyl peroxide, CCl_4 , reflux; (b) **5**, KI, DIPEA, DMF, RT; (c) LiOH, 1:1 THF: H_2O , RT; (d) *N,N'*-dicyclohexylcarbodiimide, *N*-hydroxysuccinimide, THF, RT; (e) tetra-amine functionalized fibrin binding peptide, cat. DMAP, DIPEA, DMF, RT; (f) 91:3:3:3 TFA:methanesulfonic acid:1-dodecanethiol: H_2O , RT; (g) MnCl_2 , pH 6.5. The structures of **8** and **9** are shown in Figure S7.

of the nicotinoyl methyl ester to yield **7**; subsequent NHS activation yielded the *O*-protected, bifunctional chelate. Four mol equiv of $t\text{Bu-PyC3A-NHS}$ were coupled to the tetra-amine functionalized peptide,⁵¹ to yield **8** (Figure S7). *O*-deprotection of **8** yielded the tetrameric peptide-chelate conjugate **9** (Figure S7). Mn-FBP was prepared by stirring **9** with MnCl_2 at pH 6.5. EP-2104 shares the same structure as Mn-FBP except the 4 Mn-chelates are replaced by 4 $[\text{Gd}(\text{DOTAGA})(\text{H}_2\text{O})]^-$ chelates (Figure S7).

Mn-FBP Is a High Relaxivity Probe with High Affinity to Fibrin. The per Mn relaxivity of Mn-FBP is increased 4-fold compared to $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ ($r_1 = 8.5$ vs $2.1 \text{ mM}^{-1} \text{ s}^{-1}$, respectively), owing to the larger size and slower rotational diffusion⁵⁹ of the peptide-chelate conjugate, Figure 4A.




Figure 4. (A) r_1 of Mn-FBP measured in pH 7.4 Tris buffer, bovine blood plasma, 4.5 wt %/v BSA, human fibrinogen and human fibrin gel at 1.4T, 37 °C. The 60% r_1 increase in the presence of fibrin gel is the result of the reduction in Mn-FBP tumbling rate upon protein binding. (B) Fluorescence polarization anisotropy of fluorescein labeled fibrin binding peptide in DD(E) solution as a function of added Mn-FBP (filled circles) or EP2104R (open circles) to determine K_i to DD(E).

Relaxivity is unchanged when measured in human fibrinogen solution, but increases to $13.5 \text{ mM}^{-1} \text{ s}^{-1}$ when the fibrinogen is converted to a fibrin gel. This 60% increase in relaxivity in the presence of fibrin is expected due to further slowing of rotation upon binding and is similar to what is observed with EP2104R, Figure S13.⁵¹ The lack of relaxivity increase in fibrinogen




Figure 5. Molecular MR imaging of carotid artery thrombus in a rat model with Mn-FBP. Axial T_1 -weighted images before (A, C) and 35 min after intravenous administration of Mn-FBP (B, D) at 1.5T. (C) and (D) are expanded regions from (A) and (B), respectively showing the common carotid arteries. Mn-FBP generates marked signal enhancement in the ipsilateral vessel (open arrow, D) after Mn-FBP injection, but not in contralateral vessel (filled arrow, D) or in the vessel prior to Mn-FBP injection (C). (E) Hematoxylin and Eosin stained sections of contralateral (left) and ipsilateral (right) carotid arteries showing occlusive thrombus in the injured vessel; scale bar = 300 μm . (F) and (G) show normalized signal-to-noise ratio (nSNR) of the thrombus (closed circles), contralateral vessel region (open circles), and muscle (closed diamonds) following administration of Mn-FBP and EP2104R, respectively, showing persistently enhanced thrombus with each probe and washout of signal from background tissue. (H) and (I) contrast-to-noise ratio (CNR) of thrombus-to-muscle (closed circles) and contralateral vessel region-to-muscle (open circles) following administration of Mn-FBP and EP2104R, respectively, showing large and persistently high CNR for the thrombus with each probe. $N = 4$ for each probe, error bars represent standard error of the mean.

suggests no binding to this protein. There is an intermediate increase in relaxivity when measured in bovine blood plasma ($10.7 \text{ mM}^{-1} \text{ s}^{-1}$) or BSA solution ($11.4 \text{ mM}^{-1} \text{ s}^{-1}$) suggesting some weak interaction with albumin. The molecular relaxivity of Mn-FBP is 4-fold higher than the per Mn values and this high relaxivity is required for in vivo thrombus imaging.

We measured the affinity of Mn-FBP to the soluble fibrin fragment DD(E), by measuring the displacement of a fluorescent peptide from this protein (Figure 4B, fluorescent peptide in Figure S7).⁴⁹ Mn-FBP showed nanomolar affinity for DD(E), $K_d = 110 \text{ nM}$ compared to a $K_d = 240 \text{ nM}$ for EP-2104R measured with the same DD(E) preparation.

Variable temperature ^{17}O NMR indicated that Mn-FBP is $q = 1$ with $k_{\text{ex}} = 1.1 \times 10^8 \text{ s}^{-1}$ (Figure S14, Table 2). Clearly the $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ solution structure and water exchange dynamics are negligibly affected by conjugation to the larger peptide structure, and its high relaxivity properties are maintained.

Mn-FBP Detects Arterial Thrombus. We used a clinical 1.5 T MR scanner to compare the ability of Mn-FBP to detect carotid artery thrombosis in a rat model with that of EP-2104R. A thrombus was generated in the right carotid artery by application of AlCl_3 solution to the vessel wall. A flow deficit at the site of injury was identified by time-of-flight (TOF) MR angiography (Figure S15). Thrombus formation was further confirmed by histology. For thrombus detection we used a 3D T_1 -weighted gradient echo sequence with arterial inflow suppression. Imaging was performed prior to- and immediately

following femoral artery injection of $10 \mu\text{mol/kg}$ Mn-FBP or EP-2104R ($40 \mu\text{mol/kg}$ Mn or Gd). Scanning was repeated for a period of 1h post injection to assess the dynamics of thrombus uptake ($N = 4$ per probe).

Figure 5A shows an axial T_1 -weighted image taken before Mn-FBP injection. The region containing the carotid arteries is expanded in Figure 5C and the presence of thrombus cannot be observed in this image. Figure 5B and 5D show the same image slice 35 min after Mn-FBP injection where there is strong signal enhancement in the injured carotid but no enhancement in the contralateral vessel. Histological staining confirming thrombosis at the site of enhancement is shown in Figure 5E. Sagittal images depicting the extent of the thrombus are shown in Figure S16.

We quantified the imaging by measuring nSNR for thrombus, contralateral vessel and muscle as a function of time (Figure 5F). Probe accumulation in the thrombus is readily apparent by an 80% increase in nSNR. Our positive control, EP-2104R also showed strong thrombus enhancement (Figure 5G) with a peak nSNR increase that is smaller than, but not statistically different than the increase with Mn-FBP. We also calculated the contrast-to-noise ratio (CNR) between thrombus and muscle and between contralateral vessel and muscle as a function of time for Mn-FBP and EP-2104R, Figure 5H and 5I, respectively. For Mn-FBP, thrombus-to-muscle CNR increased more than 5-fold post injection and remained high through the course of the study. Thrombi were highly conspicuous with CNR reaching a plateau by 35 min post Mn-




Figure 6. (A) Concentration of Mn or Gd in rat tissues (nmol metal per g tissue) 1.5 h after intravenous administration of 40 μmol metal ion per kg body weight of Mn-FBP (black bars), EP2104R (gray bars), and MnCl₂ (blue bars); Mn levels are corrected for endogenous baseline metal content, $N = 4$ per probe. (B) Concentration (nmol/g) of Mn in rat tissues at 24 h following Mn-FBP administration (black bars, $N = 4$) or in naïve rats (gray bars, $N = 4$, showing endogenous Mn levels). Statistically significant differences (*, $P < 0.05$) were observed in kidney and muscle and represent 0.37 ± 0.14 and $0.02 \pm 0.02\%$ of the injected dose per gram tissue, respectively. (C) LC-ICP-MS traces of plasma analyzed for Mn from blood drawn 2 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 24 h (front to back) after intravenous Mn-FBP injection. Mn-FBP elutes at 8.5 min; no species arising from dechelated Mn are detected in the LC-ICP-MS traces. (D–F) Pharmacokinetic data ($N = 4$) showing blood clearance of total Mn (D), Mn-FBP (E), and the metabolite eluting at 3.1 min (F), demonstrating rapid blood elimination of Mn-FBP and its metabolite. Error bars represent standard error of the mean; solid lines are biexponential fits to the mean data.

FBP with peak thrombus-to-muscle CNR = 32.9 ± 4.0 vs 5.6 ± 1.5 for the contralateral vessel-to-muscle CNR ($P = 0.0001$).

EP-2104R also identified the thrombi with high conspicuity, Figure S1, and the peak thrombus-to-muscle CNR was smaller than, but not statistically different than for Mn-FBP. Sample images acquired using EP2104R are shown in Figure S17. On the other hand, thrombi were not readily identifiable in the baseline scans; thrombus-to-muscle vs contralateral vessel-to-muscle CNR = 6.0 ± 5.2 vs 3.5 ± 2.4 , respectively ($N = 8$, $P = 0.23$).

Mn-FBP Is Eliminated Intact after Injection. We measured the biodistribution of Mn-FBP in rats at 1.5 and 24 h post injection by Mn ICP-MS, Figure 6A,B. To account for endogenous Mn, we also measured the organ distribution of Mn in naïve rats. Most of the Mn-FBP ($90 \pm 3\%$) was excreted into the urine by 1.5 h. Figure 6A displays nmol recovered Mn or Gd per gram tissue at 1.5 h after intravenous injection of Mn-FBP, EP2104R, and MnCl₂ (all dosed at 40 μmol metal ion per kg body weight). The distributions of Mn and Gd are very similar at 1.5 h; unchelated Mn²⁺ distributes very differently and is highly accumulated in tissues such as the heart, liver and bone. Like EP2104R, Mn-FBP is largely cleared by 1.5 h, with a little Mn remaining in the kidneys ($1.7 \pm 0.2\%$ ID/g). In Figure 6B we show the concentration of Mn in different tissues 24 h after Mn-FBP injection and the endogenous Mn concentrations found in naïve rats. At 24 h almost all of the Mn is eliminated with $<0.5\%$ ID/g in the kidneys. The only tissues with significantly higher Mn concentrations than basal levels are the kidneys and muscle at this time point.

The Mn blood pharmacokinetics were analyzed by ICP-MS using blood drawn between 0 and 24 h following probe injection. Figure 6D depicts the mean blood Mn concentrations from the 4 animals as a function of time. Total Mn blood clearance ($t_{1/2} = 22.6 \pm 6.8$ min, calculated from biexponential fits to the individual animal data) mirrors the probe clearance kinetics observed with other molecular imaging probes derived from the same fibrin binding peptide.⁵⁴

We also analyzed Mn speciation in blood plasma. This was performed using HPLC coupled ICP-MS for Mn detection. The Mn chromatograms revealed no evidence of Mn dechelation (Figure 6C). Two species are present in blood plasma, Mn-FBP ($t_{1/2} = 23.5 \pm 13.4$ min, Figure 6E) and a small, unidentified Mn-FBP degradation product that also clears over the course of the study (Figure 6F). This degradation product also arises after *in vitro* plasma incubation of Mn-FBP but is not identified after incubation with MnCl₂ (Figure S18). Thus, the new species does not correspond to free Mn²⁺ or any Mn-containing species that arise after Mn dechelation. The HPLC-ICP-MS experiments suggest negligible concentrations of species arising from dechelated Mn.

DISCUSSION

Our investigation demonstrates that a rationally designed Mn²⁺-based imaging probe can achieve high relaxivity without undergoing significant *in vivo* dissociation. The [Mn(PyC3A)-(H₂O)]⁻ complex has plasma relaxivity comparable to clinically used Gd-based contrast agents, and is one of the most thermodynamically stable and kinetically inert Mn²⁺ complexes

with respect to Mn dechelation. In mice, the complex is rapidly eliminated from the body via mixed renal and hepatic pathways and less than 1% of the injected dose remains in the body at 24 h after injection. The $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ complex can be easily modified to incorporate into targeted molecular imaging probes without loss of stability or relaxivity. Indeed, the biophysical strategies used to enhance relaxivity in Gd complexes all apply to divalent Mn as well. The fibrin targeted probe Mn-FBP was prepared with enhanced relaxivity owing to an optimization of the rotational correlation time relative to the simple chelate, fast water exchange, and multimerization. In vivo, Mn-FBP was functionally equivalent to the state of the art Gd fibrin probe EP-2104R. Using a clinical MRI scanner, we could easily detect arterial blood clots as regions of bright signal after Mn-FBP injection. Importantly, Mn-FBP was rapidly and completely eliminated from the body in a largely unchanged state. While some probe metabolism was observed, it was not related to dechelated Mn. These findings support the use of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ and its derivatives as alternatives to Gd-based contrast agents.

Gadolinium-based contrast agents are entrenched in clinical radiology. Over half of the MRI procedures at our institution employ a Gd-based contrast agent. Several factors feature in their success: the compounds are extremely safe in their intended population; they provide positive signal change that is easy to interpret; diagnostic images can be obtained shortly after injection. The major limitation of Gd-based contrast agents is their risk in the renally impaired patient population. Mn-based imaging probes represent the most broadly feasible method solution to provide contrast-enhanced images in patients contraindicated for iodinated CT contrast and/or Gd. Discrete Mn^{2+} complexes also produce positive image contrast, have similar pharmacokinetic and pharmacodynamic behavior to analogous Gd-complexes, and can be prepared as hydrophilic complexes with low nonspecific protein binding. Mn^{2+} relaxation enhancement is similar in magnitude to Gd-based complexes, and thus the effective dose is similar between Mn and Gd. A key difference between Mn^{2+} and Gd^{3+} is the distribution of the free ion. If there is some dechelation of Mn, there is an efficient, endogenous elimination pathway through the hepatobiliary system. Such a path does not exist for Gd and accumulation and toxicity can occur.

Alternate contrast enhancing approaches have limitations with respect to replacing Gd. Paramagnetic nanoparticles have unfavorable pharmacokinetics that limit their use to blood vessel or liver imaging, or require a long delay after injection for target accumulation and/or background clearance. Probes detected via CEST or direct nuclear observation require an order of magnitude higher dose than Gd or Mn which raises toxicity concerns, especially in a renally compromised population. Hyperpolarized techniques require expensive changes in hardware and the need for an onsite polarizer; Mn probes on the other hand are shelf stable.

The longstanding challenge for Mn^{2+} probes is the instability and high lability of the complexes. High spin Mn^{2+} has no ligand field stabilization energy to reduce metal ion lability, and Mn^{2+} is at the low end of the Irving–Williams series with respect to thermodynamic stability. For MR applications, an inner-sphere water ligand is required and this results in sacrificing a donor group in the multidentate ligand designed to chelate the Mn. The PyC3A chelator is a hexadentate ligand that forms a 7-coordinate ternary complex with Mn^{2+} , leaving a site for water to coordinate. The *trans*-cyclohexylene backbone

provides preorganization to enhance both stability and inertness, while the pyridyl moiety improves inertness relative to an acetate donor group. Remarkably, the complex is more inert to Zn transmetalation than $[\text{Gd}(\text{DTPA})(\text{H}_2\text{O})]^{2-}$. Overall, this combination of stability and inertness is sufficient to maintain in vivo fidelity. The cyclohexylene and pyridyl components of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ provide a modest lipophilicity to the anionic complex which promotes some hepatic uptake and elimination.

We hypothesize that $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ and its derivatives can be effective replacements for Gd-based contrast agents, especially in populations where Gd usage carries additional risk. The Mn-FBP studies indicate the stability of the Mn-chelate in vivo. In a patient with low GFR where the Mn-chelate may circulate longer, we expect that any slowly released Mn^{2+} will be eliminated through the liver. We note that $\text{Mn}[\text{DPDP}]^{3-}$ was safely used in thousands of patients and this complex is extremely unstable with respect to Mn^{2+} dechelation ($[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ is $>10^5$ times more stable than $[\text{Mn}(\text{DPDP})]^{3-}$ at pH 7.4).

A limitation of our study is that we did not formally address the toxicity of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ and Mn-FBP, nor study their in vivo behavior in a model of chronic kidney disease. The goal of the current work was to design a better chelator for Mn^{2+} and to establish that the resultant complex is stable in vivo and enables elimination of Mn. Formal studies of the safety and efficacy of these compounds in models of renal disease are planned. However, we note that our imaging and biodistribution studies in rats showed no signs of acute toxicity.

CONCLUSION

Rationally designed $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ achieves the optimal balance of thermodynamic stability, kinetic inertness and high relaxivity demanded of a MR imaging probe. The probe provides excellent MR contrast and is rapidly and completely eliminated from the body via renal and hepatic pathways. $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$ lends nicely to synthetic modulation, and we prepared a bifunctional derivative for bioconjugation. The fibrin-targeted conjugate Mn-FBP, provides strong enhancement of carotid artery thrombosis with conspicuity equivalent to the state of the art Gd-based probe EP-2104R. Mn-FBP is highly stable with respect to Mn dechelation in vivo and promotes whole body Mn clearance. The combined results of our physicochemical, MR imaging, and pharmacokinetics experiments indicate that $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$, both on its own and as a bifunctional synthon, is a lead candidate for developing non-Gd MR imaging probes.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.5b10748.

Experimental details, synthetic procedures, compound characterization, structures of molecules not depicted in main text, pH-dependent speciation of $[\text{Mn}(\text{PyC3A})(\text{H}_2\text{O})]^-$, thermodynamic, kinetic, relaxivity and water exchange parameters of Mn and Gd complexes, additional MR images, and LC-ICP-MS traces. (PDF)

AUTHOR INFORMATION

Corresponding Authors

*egale@nmr.mgh.harvard.edu

*caravan@nmr.mgh.harvard.edu

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by grants from the National Cancer Institute (T32CA009502 to E.M.G, R01CA161221 to P.C.) and the National Institute for Biomedical Imaging and Bioengineering (R01EB009062 to P.C.) and instrumentation funded by the National Center for Research Resources and the Office of the Director (RR14075, OD010650). I.P.A was supported by a fellowship from the Comunidad de Madrid and the Madrid MIT M+Vision Consortium.

REFERENCES

- (1) United States Renal Data System, 2014 USRDS annual data report: An overview of the epidemiology of kidney disease in the United States, National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, 2014.
- (2) Gullion, C. M.; Keith, D. S.; Nichols, G. A.; Smith, D. H. *Am. J. Kidney Dis.* **2006**, *48*, 212.
- (3) Shastri, S.; Samak, M. J. *Am. J. Kidney Dis.* **2010**, *56*, 399.
- (4) Hage, F. G.; Venkataraman, R.; Zoghbi, G. J.; Perry, G. J.; DeMattos, A. M.; Iskandrian, A. E. *J. Am. Coll. Cardiol.* **2009**, *53*, 2129.
- (5) Coresh, J.; Selvin, E.; Stevens, L. A.; Manzi, J.; Kusek, J. W.; Eggers, P.; Van Lente, F.; Levy, A. S. *J. Am. Med. Assoc.* **2007**, *298*, 2038.
- (6) Nash, K.; Hafeez, A.; Hou, S. *Am. J. Kidney Dis.* **2002**, *39*, 930.
- (7) Solomon, R. J.; Natarajan, M. K.; Doucet, S.; Sharma, S. K.; Staniloae, C. S.; Katholi, R. E.; Gelormini, J. L.; Labinaz, M.; Moreyra, A. E. *Circulation* **2007**, *115*, 3189.
- (8) Grobner, T. *Nephrol., Dial., Transplant.* **2006**, *21*, 1104.
- (9) Marckmann, P.; Skov, L.; Rossen, K.; Dupont, A.; Damholt, M. B.; Heaf, J. G.; Thomsen, H. S. *J. Am. Soc. Nephrol.* **2006**, *17*, 2359.
- (10) Yang, L.; Krefting, I.; Gorovets, A.; Marzella, L.; Kaiser, J.; Boucher, R.; Rieves, D. *Radiology* **2012**, *265*, 248.
- (11) ACR Manual on Contrast Media v 10.1; American College of Radiology: USA, 2015.
- (12) Besheli, L. D.; Aran, S.; Shaqdan, K.; Kay, J.; Abujudeh, H. *Clin. Radiol.* **2014**, *69*, 661.
- (13) Kanda, T.; Fukusato, T.; Matsuda, M.; Toyoda, K.; Oba, H.; Kotoku, J.; Haruyama, T.; Kitajima, K.; Furui, S. *Radiology* **2015**, *276*, 228.
- (14) Kanda, T.; Osawa, M.; Oba, H.; Toyoda, K.; Kotoku, J.; Haruyama, T. *Radiology* **2015**, *275*, 803.
- (15) Kanda, T.; Ishii, K.; Kawaguchi, H.; Kitajima, K.; Takenaka, D. *Radiology* **2014**, *270*, 834.
- (16) Kanda, T.; Kawaguchi, H. *Neuroradiology* **2013**, *55*, 1268.
- (17) McDonald, R. J.; McDonald, J. S.; Kallmes, D. F.; Jentoft, M. E.; Murray, D. L.; Thielen, K. R.; Williamson, E. E.; Eckel, L. J. *Radiology* **2015**, *275*, 772.
- (18) Kanal, E.; Tweedle, M. F. *Radiology* **2015**, *275*, 630.
- (19) Bashir, M. R.; Bhatti, L.; Marin, D.; Nelson, R. C. *J. Magn. Res. Imag.* **2015**, *41*, 884.
- (20) FDA Orders Stricter Warnings for Ferumoxytol (Feraheme) [online] Medscape **2015**, <http://www.medscape.com/viewarticle/842309> (accessed March 30, 2015).
- (21) Aime, S.; Castelli, D. D.; Geninatti, S.; Gianolio, E.; Terreno, E. *Acc. Chem. Res.* **2009**, *42*, 822.
- (22) Boros, E.; Gale, E. M.; Caravan, P. *Dalton Trans.* **2015**, *44*, 4804.
- (23) Lauffer, R. B. *Chem. Rev.* **1987**, *87*, 901.
- (24) Hamm, B.; Vogl, T. J.; Branding, G.; Schnell, B.; Taupitz, M.; Wofk, K.-J.; Lissner, J. *Radiology* **1992**, *182*, 167.
- (25) Vogl, T. J.; Hamm, B.; Schnell, B.; McMahon, C.; Branding, G.; Lissner, J.; Wolf, K.-J. *J. Magn. Res. Imag.* **1993**, *3*, 51.
- (26) Gallez, B.; Bacic, G.; Swartz, H. M. *Magn. Reson. Med.* **1996**, *35*, 14.
- (27) Ni, Y.; Petré, C.; Bosmans, H.; Miao, Y.; Grant, D.; Baert, A. L.; Marchal, G. *Acta Radiol.* **1997**, *38*, 700.
- (28) Chandra, T.; Pukenas, B.; Mohan, S.; Melhem, E. *Magn. Reson. Imaging Clin. N. Am.* **2012**, *20*, 687.
- (29) Leiner, T.; Michaely, H. *Magn. Reson. Imaging Clin. N. Am.* **2008**, *16*, 561.
- (30) Moon, M.; Cornfield, D.; Weinreb, J. *Magn. Reson. Imaging Clin. N. Am.* **2009**, *2*.
- (31) Essig, M.; Dinkel, J.; Gutierrez, J. E. *Magn. Reson. Imaging Clin. N. Am.* **2012**, *20*, 633.
- (32) Keston, P.; Murray, A. D.; Jackson, A. *Clin. Radiol.* **2003**, *58*, 505.
- (33) Kálmán, F. K.; Tircsó, G. *Inorg. Chem.* **2012**, *51*, 10065.
- (34) Gale, E. M.; Mukherjee, S.; Liu, C.; Loving, G. S.; Caravan, P. *Inorg. Chem.* **2014**, *53*, 10748.
- (35) Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B. *Chem. Rev.* **1999**, *99*, 2293.
- (36) Aime, S.; Anelli, P. L.; Botta, M.; Brocchetta, M.; Canton, S.; Fedeli, F.; Gianolio, E.; Terreno, E. *JBIC, J. Biol. Inorg. Chem.* **2002**, *7*, 58.
- (37) Troughton, J. S.; Greenfield, M. T.; Greenwood, J. M.; Dumas, S.; Wiethoff, A. J.; Wang, J.; Spiller, M.; McMurry, T. J.; Caravan, P. *Inorg. Chem.* **2004**, *43*, 6313.
- (38) Maigut, J.; Meier, R.; Zahl, A.; van Eldik, R. *Inorg. Chem.* **2008**, *47*, 5702.
- (39) Drahoš, B.; Lukeš, I.; Tóth, E. *Eur. J. Inorg. Chem.* **2012**, *2012*, 1975.
- (40) Caravan, P.; Rettig, S. J.; Orvig, C. *Inorg. Chem.* **1997**, *36*, 1306.
- (41) Caravan, P.; Farrar, C. T.; Frullano, L.; Uppal, R. *Contrast Media Mol. Imaging* **2009**, *4*, 89.
- (42) Drahoš, B.; Kubiček, V.; Bonnet, C. S.; Hermann, P.; Lukeš, I.; Tóth, E. *Dalton Trans.* **2011**, *40*, 1945.
- (43) Drahoš, B.; Pniok, M.; Havlíčková, J.; Kotek, J.; Císařová, I.; Hermann, P.; Lukeš, I.; Tóth, E. *Dalton Trans.* **2011**, *30*, 10131.
- (44) Drahoš, B.; Kotek, J.; Císařová, I.; Hermann, P.; Helm, L.; Lukeš, I.; Tóth, E. *Inorg. Chem.* **2011**, *50*, 12785.
- (45) Drahoš, B.; Kotek, J.; Hermann, P.; Lukeš, I.; Tóth, E. *Inorg. Chem.* **2010**, *49*, 3224.
- (46) Gale, E. M.; Zhu, J.; Caravan, P. *J. Am. Chem. Soc.* **2013**, *135*, 18600.
- (47) Caravan, P.; Parigi, G.; Chasse, J. M.; Cloutier, N. J.; Ellison, J. J.; Lauffer, R. B.; Luchinat, C.; McDermid, S. A.; Spiller, M.; McMurry, T. J. *Inorg. Chem.* **2007**, *46*, 6632.
- (48) Rohrer, M.; Bauer, H.; Mintorovitch, J.; Requardt, M.; Weinmann, H.-J. *Invest. Radiol.* **2005**, *40*, 715.
- (49) Kolodziej, A. F.; Nair, S. A.; Graham, P.; McMurry, T. J.; Ladner, R. C.; Wescott, C.; Sexton, D. J.; Caravan, P. *Bioconjugate Chem.* **2012**, *23*, 548.
- (50) Kolodziej, A. F.; Zhang, Z.; Overoye-Chan, K.; Jacques, V.; Caravan, P. *Methods Mol. Biol.* **2014**, *1088*, 185.
- (51) Overoye-Chan, K.; Koerner, S.; Looby, R. J.; Kolodziej, A. F.; Zech, S. G.; Deng, Q.; Chasse, J. M.; McMurry, T. J.; Caravan, P. *J. Am. Chem. Soc.* **2008**, *130*, 6025.
- (52) Uppal, R.; Medarova, Z.; Farrar, C. T.; Dai, G.; Moore, A.; Caravan, P. *Invest. Radiol.* **2012**, *47*, 553.
- (53) Uppal, R.; Catana, C.; Ay, I.; Benner, T.; Sorenson, A. G.; Caravan, P. *Radiology* **2011**, *258*, 812.
- (54) Blasi, F.; Oliveria, B. L.; Rietz, T. A.; Rötter, N. J.; Day, H.; Looby, R. J.; Ay, I.; Caravan, P. *J. Nucl. Med.* **2014**, *55*, 1157.
- (55) Ay, I.; Blasi, F.; Rietz, T. A.; Rötter, N. J.; Kura, S.; Brownell, A. L.; Day, H.; Oliveria, B. L.; Looby, R. J.; Caravan, P. *Circ. Cardiovasc. Imaging* **2014**, *7*, 697.
- (56) Ciesiński, K. L.; Yang, Y.; Ay, I.; Chonde, D. B.; Loving, G. S.; Rietz, T. A.; Catana, C.; Caravan, P. *Mol. Pharmaceutics* **2013**, *56*, 1782.
- (57) Vymazal, J.; Spuentrup, E.; Cardenas-Molina, G.; Wiethoff, A. J.; Hartmann, M. G.; Caravan, P.; Parsons, E. C., Jr. *Invest. Radiol.* **2009**, *44*, 697.

- (58) Spuentrup, E.; Botnar, R. M.; Wiethoff, A. J.; Ibrahim, T.; Kelle, S.; Katoh, M.; Ozgun, M.; Nagel, E.; Vymazal, J.; Graham, P. B.; Günther, R. W.; Maintz, D. *Eur. Radiol.* **2008**, *18*, 1995.
- (59) Zhou, X.; Caravan, P.; Clarkson, R. B.; Westlund, P. O. *J. Magn. Reson.* **2004**, *167*, 147.